Abstract
Although expanded access to antiretroviral therapy (ART) in Africa has greatly improved survival, early mortality after ART initiation remains high. Cryptococcal infection and tuberculosis (TB) account for most of the early deaths, and cost-effective strategies are needed to improve outcomes. In an open-label, controlled study conducted in Tanzania and Zambia, researchers assessed one such strategy: screening for cryptococcal antigen (CrAg) before ART initiation (and treating those with positive …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
